Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07312773) titled 'A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Addpharma Inc.
Condition:
Hypertension
Hyperlipidemia
Intervention:
Drug: Treatment A(AD-231A)
Drug: Treatment B(AD-231B+AD-231C)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: January 23, 2026
Target Sample Size: 55
Countries of Recruitment:
South Korea
To know more, visit ...